Create Medicines

Create Medicines is developing a novel class of immunotherapies via its proprietary in vivo CAR platform, which uses mRNA-LNP formulations to program multiple immune cell types directly in the body. This approach seeks to overcome the manufacturing complexity, cost, and time constraints of ex vivo cell therapies. The company has generated first-in-human clinical data confirming mechanism of action and is advancing a pipeline with programs in Phase 1 and Phase 2 for solid tumors and hematologic malignancies. Founded in 2021 and based in Boston, CREATE is a private, pre-revenue company positioning itself at the forefront of scalable, off-the-shelf cell therapy.

Proprietary in vivo immune cell programming platform using mRNA-encoded CARs delivered via targeted lipid nanoparticles (LNPs). Capable of multi-lineage programming of T cells, NK cells, and myeloid cells directly within the patient's body.

CREATE competes in the emerging field of in vivo cell engineering against companies like Umoja Biopharma, Capstan Therapeutics, and Ensoma, as well as large biopharma partners exploring LNP-mRNA delivery for cell therapy. Differentiation hinges on proprietary receptor/LNP targeting, multi-cell programming capability, and clinical proof-of-concept.